Evidence map›Paper›PMID 42174382›Full record

ArticleChemMedChem2026

Ligand-Based Pharmacophore Modeling and Structure-Based Virtual Screening for Identifying Potential Therapeutic Agents Targeting the SARS-CoV-2 Spike Protein-ACE2 Receptor Interaction.

Timoteo Delgado-Maldonado, Gilberto Vargas-Salas, Debasish Bandyopadhyay, Adriana Moreno-Rodríguez, Eyra Ortiz-Pérez, Gildardo Rivera

Abstract read
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Timoteo Delgado-MaldonadoLaboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México.
Gilberto Vargas-SalasLaboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México.
Debasish BandyopadhyaySchool of Integrative Biological and Chemical Sciences (SIBCS) & School of Earth, Environmental, and Marine Sciences (SEEMS), University of Texas Rio Grande Valley, Edinburg, Texas, USA.
Adriana Moreno-RodríguezLaboratorio de estudios Epidemiológicos, Clínicos, Diseños Experimentales e Investigación, Facultad de ciencias Químicas, Universidad Autónoma "Benito Juárez" de Oaxaca, Oaxaca, México.
Eyra Ortiz-PérezLaboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México.
Gildardo RiveraLaboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, México.ORCID 0000-0001-9842-4167

Funding

Secretaría de Investigación y Posgrado, Instituto Politécnico Nacional Grant 20250835
6 · The paper itself

Abstract

Coronavirus disease (COVID-19) remains a global health concern due to its high mortality and morbidity. In this study, we combined ligand-based pharmacophore modeling (LBPM) with structure-based virtual screening (SBVS) to identify novel inhibitors targeting the SARS-CoV-2 spike protein. Ligands from the MolPort database were screened via docking and molecular dynamics simulations at the receptor-binding domain (RBD). Four compounds showed promising docking scores (-8.7 to -6.4 kcal/mol) and dynamic stability (root mean square deviation < 5 Å). In vitro assays confirmed that compounds C3 (IC

Indexed as

Angiotensin-Converting Enzyme 2Antiviral AgentsSARS-CoV-2Spike Glycoprotein, CoronavirusBetacoronavirusDrug Evaluation, PreclinicalHumansLigandsMolecular Docking SimulationMolecular Dynamics SimulationPharmacophoreProtein BindingStructure-Activity RelationshipACE2 protein, humanAngiotensin-Converting Enzyme 2Antiviral AgentsLigandsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-21H‐pyrazol‐5‐ol derivativesinhibitors viral entrypharmacophore modeling validationSARS‐CoV‐2 spike protein

Identifiers

PMID42174382
PMCPMC13206590

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.